Calidi Biotherapeutics (CLDI) EBIT (2022 - 2026)

Calidi Biotherapeutics has reported EBIT for 5 years, with the latest figure at -$4.1 million in Q2 2026.

• On a quarterly basis, EBIT rose 26.73% year-over-year to -$4.1 million in Q2 2026; TTM through Jun 2026 was -$19.3 million, a 3.25% increase from a year earlier, with the FY2025 full-year figure at -$20.2 million, up 7.05% from the prior year.
• EBIT was -$4.1 million for Q2 2026 at Calidi Biotherapeutics, up from -$4.5 million in the prior quarter.
• The five-year high for EBIT was -$361622.0 in Q2 2022, with the low at -$9.8 million in Q4 2023.
• Average EBIT over 5 years is -$5.2 million, with a median of -$5.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: EBIT tumbled 1707.69% in 2023, then soared 59.0% in 2024.
• Over 5 years, EBIT stood at -$4.7 million in 2022, then plunged by 109.47% to -$9.8 million in 2023, then jumped by 59.0% to -$4.0 million in 2024, then dropped by 10.93% to -$4.5 million in 2025, then advanced by 7.08% to -$4.1 million in 2026.
• The last three EBIT figures came in at -$4.1 million (Q2 2026), -$4.5 million (Q4 2025), and -$5.0 million (Q3 2025), per Business Quant data.